Added to YB: 2026-08-12
Pitch date: 2026-08-09
TMDX [neutral]
TransMedics Group, Inc.
+8.16%
current return
Author Info
No bio for this author
Company Info
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally.
Market Cap
$2.9B
Pitch Price
$82.62
Price Target
N/A
Dividend
N/A
EV/EBITDA
26.60
P/E
20.90
EV/Sales
4.94
Sector
Health Care Equipment and Supplies
Category
growth
MM Top Ideas List: 20 Stocks Worth Watching - TransMedics Group, Inc.
TMDX (overview): Organ transplant disruptor via OCS (heart/liver/lung, 24hr preservation) + vertically integrated NOP w/ aviation network. Kidney (Gen 3.0) is next, bigger than all others combined. EU expansion via PAD Aviation. Targets 10k US transplants '28, 30k global '32 vs ~5k last yr. 24x '28 net income (inflated by growth spend).
Read full article (1 min)